Literature DB >> 15386661

Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.

Elamin H Elbasha1.   

Abstract

The availability of patient-level data from clinical trials has spurred a lot of interest in developing methods for quantifying and presenting uncertainty in cost-effectiveness analysis (CEA). Although the majority has focused on developing methods for using sample data to estimate a confidence interval for an incremental cost-effectiveness ratio (ICER), a small strand of the literature has emphasized the importance of incorporating risk preferences and the trade-off between the mean and the variance of returns to investment in health and medicine (mean-variance analysis). This paper shows how the exponential utility-moment-generating function approach is a natural extension to this branch of the literature for modelling choices from healthcare interventions with uncertain costs and effects. The paper assumes an exponential utility function, which implies constant absolute risk aversion, and is based on the fact that the expected value of this function results in a convenient expression that depends only on the moment-generating function of the random variables. The mean-variance approach is shown to be a special case of this more general framework. The paper characterizes the solution to the resource allocation problem using standard optimization techniques and derives the summary measure researchers need to estimate for each programme, when the assumption of risk neutrality does not hold, and compares it to the standard incremental cost-effectiveness ratio. The importance of choosing the correct distribution of costs and effects and the issues related to estimation of the parameters of the distribution are also discussed. An empirical example to illustrate the methods and concepts is provided. Copyright 2004 John Wiley & Sons, Ltd

Entities:  

Mesh:

Year:  2005        PMID: 15386661     DOI: 10.1002/hec.915

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  5 in total

1.  Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

2.  Setting priorities in global child health research investments: guidelines for implementation of CHNRI method.

Authors:  Igor Rudan; Jennifer L Gibson; Shanthi Ameratunga; Shams El Arifeen; Zulfiqar A Bhutta; Maureen Black; Robert E Black; Kenneth H Brown; Harry Campbell; Ilona Carneiro; Kit Yee Chan; Daniel Chandramohan; Mickey Chopra; Simon Cousens; Gary L Darmstadt; Julie Meeks Gardner; Sonja Y Hess; Adnan A Hyder; Lydia Kapiriri; Margaret Kosek; Claudio F Lanata; Mary Ann Lansang; Joy Lawn; Mark Tomlinson; Alexander C Tsai; Jayne Webster
Journal:  Croat Med J       Date:  2008-12       Impact factor: 1.351

3.  Individualized cost-effectiveness analysis.

Authors:  John P A Ioannidis; Alan M Garber
Journal:  PLoS Med       Date:  2011-07-12       Impact factor: 11.069

4.  Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.

Authors:  Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2022-02-09       Impact factor: 4.558

5.  Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.

Authors:  Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2020-10-31       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.